JPMorgan Amends PMV Pharma Stake; Institutional Ownership Update

TL;DR

**JPMorgan updated its PMV Pharma stake, signaling a potential shift in institutional sentiment.**

AI Summary

JPMorgan Chase & Co. filed an amendment (SC 13G/A) on January 23, 2024, updating its ownership in PMV Pharmaceuticals, Inc. as of December 29, 2023. This filing indicates a change in their beneficial ownership, which is important because JPMorgan is a major institutional investor, and their adjustments can signal shifts in their confidence or strategy regarding PMV Pharmaceuticals' future prospects. Investors should note this as a potential indicator of institutional sentiment.

Why It Matters

Changes in large institutional holdings like JPMorgan's can influence stock price and reflect a major investor's updated view on the company's value or future performance.

Risk Assessment

Risk Level: low — This filing is a routine update of institutional ownership and does not inherently present a direct risk, but rather provides transparency.

Analyst Insight

Investors should monitor subsequent filings from JPMorgan Chase & Co. or other major institutions to identify a clear trend in institutional sentiment towards PMV Pharmaceuticals, Inc. This filing alone doesn't provide enough detail to warrant immediate action beyond awareness.

Key Players & Entities

• JPMorgan Chase & Co. (company) — the entity filing the SC 13G/A, reporting its ownership in PMV Pharmaceuticals, Inc.
• PMV Pharmaceuticals, Inc. (company) — the subject company in which JPMorgan Chase & Co. holds shares.
• December 29, 2023 (date) — the date of the event which required the filing of this statement.
• January 23, 2024 (date) — the date the SC 13G/A filing was made.

FAQ

Key Financial Figures

• $0.00001 — ame of Issuer) Common stock, par value $0.00001 (Title of Class of Securities) 6935

Filing Documents

• PMV_PHARMACEUTICALS_INC.ht.htm (SC 13G/A) — 86KB
• 0000019617-24-000129.txt ( ) — 88KB

From the Filing

SC 13G/A 1 PMV_PHARMACEUTICALS_INC.ht.htm FILING PMV PHARMACEUTICALS, INC. Schedule 13G UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 03 )* PMV PHARMACEUTICALS, INC. (Name of Issuer) Common stock, par value $0.00001 (Title of Class of Securities) 69353Y103 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: x Rule 13d-1(b) o Rule 13d-1(c) o Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 69353Y103 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) JPMORGAN CHASE & CO. 13-2624428 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) o (b) o 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 3,405,500 6 SHARED VOTING POWER 0 7 SOLE DISPOSITIVE POWER 3,674,814 8 SHARED DISPOSITIVE POWER 0 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,674,814 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.1 % 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC FOOTNOTES Item 1. (a) Name of Issuer PMV PHARMACEUTICALS, INC. (b) Address of Issuer's Principal Executive Offices One Research Way, Princeton, NJ 08540 Item 2. (a) Name of Person Filing JPMORGAN CHASE & CO. (b) Address of Principal Business Office or, if none, Residence 383 Madison Avenue New York, NY 10179 (c) Citizenship Delaware (d) Title of Class of Securities Common stock, par value $0.00001 (e) CUSIP Number 69353Y103 Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) o Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) o Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) o Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) o Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) o An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) o An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) x A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) o A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J). (k) o A group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 3,674,814 (b) Percent of class: 7.1 % (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 3,405,500 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 3,674,814 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5. of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o . Item 6. of More than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company J.P. Morgan Securities LLC JPMorgan Chase Bank, National Association JPMorgan Asset Management (Asia Pacific) Limited JPMorgan Asset Management (UK)

View Full Filing

View this SC 13G/A filing on SEC EDGAR